MIRA Pharmaceuticals (NASDAQ:MIRA) is developing MIRA1a, a novel synthetic analog of THC (tetrahydrocannabinol) to treat anxiety and cognitive decline in the elderly and neuropathic pain, with a lower impurity profile...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Just a few of the companies we’ve highlighted along the way
